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Background: Intra-abdominal infections are one of the most common infections encountered by a general
surgeon. However, despite this prevalence, standardized guidelines outlining the proper use of antibiotic therapy
are poorly defined due to a lack of clinical trials investigating the ideal duration of antibiotic treatment. The aim of
this study is to compare the efficacy and safety of a three-day treatment regimen of Ampicillin-Sulbactam to that of
a three-day regimen of Ertapenem in patients with localized peritonitis ranging from mild to moderate severity.
Methods: This study is a prospective, multi-center, randomized investigation performed in the Department of
General, Emergency, and Transplant Surgery of St. Orsola-Malpighi University Hospital in Bologna, Italy. Discrete data
were analyzed using the Chi-squared and Fisher exact tests. Differences between the two study groups were
considered statistically significant for p-values less than 0.05.
Results: 71 patients were treated with Ertapenem and 71 patients were treated with Ampicillin-Sulbactam. The two
groups were comparable in terms of age and gender as well as the site of abdominal infection. Post-operative
infection was identified in 12 patients: 10 with wound infections and 2 with intra-abdominal infections. In the
Ertapenem group, 69 of the 71 patients (97%) were treated successfully, while the therapy failed in 2 cases (3%).
Therapy failures were more frequent in the Unasyn group, amounting to 10 of 71 cases (p = 0.03).
Conclusion: According to these preliminary findings, the authors conclude that a three-day Ertapenem treatment
regimen is the most effective antibiotic therapy for patients with localized intra-abdominal infections ranging from
mild to moderate severity.
Trial registration: ClinicalTrials.gov: NCT00630513Background
Intra-abdominal infections are one of the most common
infections encountered by a general surgeon. These infec-
tions are difficult to diagnose in their early stages and
effective treatment is equally challenging. Ertapenem and
Ampicillin-Sulbactam are both recommended as single
agent treatments to address localized peritonitis by the
SIS (Surgical Infections Society) and the IDSA (Infection
Diseases Society of America). According to these guide-
lines, “an antimicrobial therapy for established infections
should be continued until resolution of clinical signs of
infection occurs, including normalization of temperature* Correspondence: lavoriscientif@hotmail.it
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reproduction in any medium, provided the orand white blood cell count and return to gastrointestinal
function” [1]. The ambiguity of these guidelines is the
result of a distinct lack of clinical trials investigating the
optimal duration of antibiotic therapy. Consequently, in
most trials involving antibiotic therapy, an arbitrarily fixed
period ranging from 5 to 14 days is used for all patients
with intra-abdominal infections, irrespective of the sever-
ity of peritonitis. Most patients enrolled in trials involving
intra-abdominal infections present with mild peritonitis
and acute appendicitis [2]. Furthermore, most cases fea-
ture localized infections or simple contamination. These
patients often receive superfluous antibiotic treatment. A
meta-analysis of twenty-eight studies investigating the
duration of antibiotic treatment in cases of advanced
pediatric appendicitis demonstrated that limiting theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with a higher rate of abdominal abscesses or
wound infection [3]. A randomized study demonstrated
that shorter duration of Ertapenem therapy is as effective
as a 5-day treatment regimen in patients with mild to
moderate peritonitis [4]. Given that overuse of antibiotics
increases treatment costs, reduces clinical efficacy, and
spurs the emergence of antibiotic-resistant pathogens and
bacterial strains [5], a conservative shift in antibiotic
methodology is of utmost importance.
The aim of this study is to compare the efficacy and
safety of a three-day treatment regimen of Ampicillin-
Sulbactam to that of a three-day regimen of Ertapenem in
patients with localized peritonitis ranging from mild to
moderate severity. All patients had a localized peritonitis.
The Basoli study demonstrated that, in patients with
localized community-acquired intraabdominal infec-
tion, a 3-day course of ertapenem had the same clinical
and bacteriological efficacy as a standard duration [4].
Ertapenem is a long-term acting parenteral Group I
carbapenem, which acts in vitro against most aerobic and
anaerobic bacteria associated with community-acquired
infections [6,7]. Although it is not active against Pseudo-
monas Aeruginosa or Enterococci, prevention of such
strains is not routinely required for intra-abdominal infec-
tions [8,9]. Ampicillin-Sulbactam is widely used in the
treatment of intra-abdominal infections. The daily dosage
is 3 g × 3 compared to Ertapenem, which is administered
as a 1-g single dose. It should be noted that, in Italy, 1 g of
Ertapenem costs 36 euros while 1 g of Ampicillin-
Sulbactam costs only 0.23 euros.
Methods
This study is a prospective, randomized investigation
performed in the Department of General, Emergency, and
Transplant Surgery at St. Orsola-Malpighi University
Hospital in Bologna, Italy, and was conducted by all
surgeons willing to participate in the study. Patients were
enrolled in the study during a two-year period, January
2008 to March 2010. The study was designed and
conducted in compliance with the regulations outlined in
“Good Clinical Practice” methodology. The efficacy of a
3-day treatment regimen of Ampicillin-Sulbactam (AS
3 g × 3/day administered intravenously) was compared
to a 3-day regimen of Ertapenem (1g/day administered
intravenously) in the treatment of patients with localized
peritonitis followed by blind evaluation of pre-established
efficacy-based endpoints. Evaluation of success or failure is
blindly assessed by designated third party administrators
who are unaware of the treatments assigned to patients [10].
Randomization
Randomization was achieved using a computer-generated
assignment system; the results were sealed in numberedenvelopes. The patient signed a document verifying
informed consent at which time the attending surgeon
disclosed the contents sealed within the assigned envelope
to determine the patient’s randomly assigned treatment
group. The attending surgeon then recorded the patient
name and envelope number.
Statistical analysis
Statistical analysis was carried out using Epi Info 2000,
Version 1.1 software package. Researchers used the con-
tinuous numerical data to perform an analysis of vari-
ance (ANOVA), given that this method can discriminate
between two continuous populations. Discrete data were
analyzed using the Chi-squared or Fisher exact tests, as
appropriate. Differences between the two study groups
were considered statistically significant for p-values less
than 0.05.
Inclusion and exclusion criteria
Inclusion criteria include the following: adulthood (> 18
years of age), surgical intervention within 24 hours of diag-
nosis, localized intra-abdominal infection, acute appendi-
citis, acute perforated diverticulitis (perforated diverticulitis
without fluid collection addressed surgically by means of
primary anastomosis), acute cholecystitis, acute gastric and
duodenal perforation (> 24 hours), traumatic perforation of
the intestine (>12 hours), secondary peritonitis due to per-
forated viscera, and intra-abdominal abscesses.
Exclusion criteria include the following: traumatic bowel
perforation requiring surgery within 12 hours, perforation
of gastrointestinal ulcer requiring surgery within 24 hours,
other intra-abdominal diseases in which the primary eti-
ology was unlikely to be infectious, lactation or pregnancy,
rapidly progressive or terminal illness, history or presence
of severe hepatic or renal disease, concomitant infections
that would interfere with the evaluation of responses to
the study antibiotics, and history of allergy, hypersensitiv-
ity, or any other severe reaction to study antibiotics [10].
Upon patient enrolment, the severity of disease was
evaluated by means of an APACHE II score prior to the
operation.
Diagnosis was based on the patient’s clinical symp-
toms, laboratory tests, and CT imaging: thereafter it was
confirmed by microbial cultures and other intra-
operative findings.
Upon enrolment, all patients underwent physical
examinations and laboratory tests, which were repeated
identically on the third day of the treatment regimen, at
the end of the treatment cycle following the resolution
of pathology, and during the post-treatment follow-up
analysis.
Preoperative percutaneous drainage was not performed,
as this procedure is not conducted in emergency settings
at our institution.
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approach and transitioned to open surgery if deemed
necessary.Table 1 Patients’ characteristics and preoperative-
intraoperative findings
Parameter Ertapenem
group
Ampicillin-
Sulbactam
group
P
Male/Female Ratio 36/35 34/37 n.
s.
Age 52,3 51 n.
s.
Apache II score > 10 7 8 n.Antibiotic therapy and data collection
The operation was performed within 24 hours of diagnosis,
and antibiotic therapy was initiated in the operating room
prior to surgery. The patient was then post-operatively
administered a 3-day treatment of either Ertapenem or
Ampicillin-Sulbactam depending on the assigned treat-
ment group. The treatment was discontinued in patients
demonstrating improved body temperature (<37.8°C), a
shift in white blood cell counts into the normal range, and
the presence of abdominal sounds by the third day of treat-
ment. Aerobic and anaerobic cultures of intra-operatively
retrieved specimens were obtained at baseline and
processed in the clinical microbiological laboratory. All
microorganisms were isolated, cultured, and tested for
in vitro susceptibility to the study antibiotics.
Upon enrolment, all patients underwent a series of
physical examinations and laboratory tests. The same ex-
aminations were performed on the third day of the treat-
ment regimen, at the end of the treatment cycle following
the resolution of pathology, and during the post-treatment
follow-up analysis. The clinical outcomes of eligible pa-
tients were categorized into three groups: successful (no
signs or symptoms of infection and no further need for
antimicrobial therapy), failure (indicating no improve-
ment, progression of infection, or death due to infection),
and late failure (indicating recurrence between cessation
of antibiotic therapy and follow-up). All adverse events
that occurred during the course of the study were care-
fully documented.s.
Phlegmonous appendicitis 11 10 n.
s.
Gangrenous appendicitis 12 11 n.
s
Appendicitis with abscess 12 10 n.
s
Localized perforated diverticulitis
without fluid collections
9 10 n.
s
Phlegmonous cholecystitis 9 10 n.
s
Gangrenous cholecystitis 9 10 n.Informed consent
Informed consent was obtained in writing from all
enrolled participants (adult patients, >18 years old). In
the informed consent document, the patient reviewed all
relevant information regarding the study protocol and
the confidentiality of personal data. After signing the
informed consent document, the patient completed a
questionnaire. The patients were permitted to withdraw
from the study at any time without any further commit-
ments or obligations.s
Perforated cholecystitis with
localized collection
8 8 n.
s
Perforated gastric ulcer 1 1 n.
s
Perforated duodenal ulcer 0 1 n.
s
Conversion to open surgery 7 8 n.
sEthical approval and study protocol
The study was approved by the Ethics Committee of St.
Orsola-Malpighi University Hospital and the study
protocol was registered with ClinicalTrials.gov under the
title “University of Bologna Protocol Record T.E.A.
Study, T.E.A. Study Three days Ertapenem versus three
days Ampicillin-sulbactam”.Primary endpoint
The primary endpoint involved comparing the clinical
efficacy and failure rate of truncated Ertapenem and
Ampicillin-Sulbactam antibiotic regimens in the treat-
ment of localized intra-abdominal infections.
Results
As demonstrated in Table 1, the two groups of patients
were comparable in terms of gender and age criteria. The
Ertapenem group consisted of 36 men and 35 women,
while the Ampicillin- Sulbactam group consisted of 37
men and 34 women. Mean patient ages were 52.3 and 51
years for the Ertapenem and Ampicillin-Sulbactam
groups, respectively. In the Ertapenem group, 35 of 71 pa-
tients presented with acute appendicitis compared to 31
cases in the Ampicillin-Sulbactam group. 9 (12.6%) and 10
(14%) patients presented with acute diverticulitis in the
Ertapenem and Unasyn groups, respectively. Patients with
peptic ulcers were rare in both groups: only 1 case in the
Ertapenem group and 2 cases in the Ampicillin-Sulbactam
group. There were not major differences between the two
groups are in term of acute cholecystitis; this condition
accounted for 36.6% of all cases in the Ertapenem group
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group (28 patients). According to Apache II Scores, 7
patients in the Ertapenem group and 8 patients in the
Ampicillin-Sulbactam group exhibited scores greater than
10. All other cases featured scores less than or equal to 10.
This demonstrates that the severity of illness typically
ranged from mild to severe, as indicated in the inclusion
criteria of this study.
The conversion rate from laparoscopic to open surgery
was comparable in both studied groups (7/71 in the
Ertapenem group and 8/71 in the Ampicillin-Sulbactam
group; p= n.s.).
As reported in Table 2, post-operative infections
occurred in 12 patients, 10 presenting with a superficial
infection and 2 with a deep intra-abdominal infection.
Both deep intra-abdominal infections and 8 of the 10
superficial infections occurred in the Ampicillin-
Sulbactam group.
Other miscellaneous morbidities involved both treat-
ment groups equally, with 21 cases in the Ertapenem
group and 19 cases in the Ampicillin-Sulbactam group
(p = n.s. Table 2). Each treatment group experienced 1
case of post-operative death.
Patients presenting with biliary leaks underwent con-
servative treatment successfully.
As reported Table 2, in the Ertapenem group, 69 of 71
patients (97%) were effectively treated, whereas the ther-
apy failed in 2 cases (3%). Therapy failures were more
frequent in the Ampicillin-Sulbactam group, amounting
to 10 of 71 cases. As such, 61 of 71 patients (86%)
underwent successful antibiotic therapy. The difference
in effectiveness of the two antibiotic treatments was
determined to be statistically significant (p = 0.03).
Superficial infections were treated in an outpatient
setting by means of repeated washes and aggressiveTable 2 Outcomes
Diagnosis Ertapenem
group
Ampicillin- Sulbactam
group
p
Superficial/Deep
Infections
2/0 8/2 0.03
Mortality 1 (AMI) 1 (PE) n.s.
Morbidity 21 19 n.s.
PE 1 1 n.s.
DVT 3 4 n.s.
AMI 1 1 n.s.
Pneumoniae 6 5 n.s.
Prolonged ileus 4 4 n.s.
UTI 3 3 n.s.
TIA 1 0 n.s.
Biliary leaks 2 1 n.s.
Cure/Failure 69/2 51/10 0.03irrigation, whereas deep infections were treated with
CT-guided percutaneous drainage and second-line anti-
biotics (piperacillin-tazobactam, 18 grams)
In the Ertapenem group, treatment failure occurred in
2 cases and was caused by Enterobacter, Staphylococci,
and Acinetobacter (Table 3).
Contrastingly, in the Ampicillin-Sulbactam group,
treatment failure occurred in 10 cases and was caused
by Enterobacter, Enterococci, Staphylococci Pseudomonas,
Serratia and Escherichia Coli (Table 3).
There were no clostridium difficile infections.
Discussion
The guidelines of the Surgical Infection Society and the
Infectious Disease Society of America state that “an anti-
microbial therapy for established infections should be
continued until resolution of clinical signs of infection
occurs, including normalization of temperature and
white blood cell count and return to gastrointestinal
function” [1]. These indications are limited and non-
specific due to a lack of clinical trials investigating the
appropriate duration of antibiotic therapy. As a conse-
quence, many studies rely on an arbitrarily determined
“default” duration of antibiotic treatment without
accounting for the severity of a particular infection.
Many patients are therefore over-treated with superflu-
ous antibiotic therapy, which increases therapy costs,
triggers adverse side-effects, and spurs the emergence of
drug-resistant pathogens. This precarious situation un-
derscores the need for clinical trials investigating the
proper duration of antibiotic therapy.
The Word Society of Emergency Surgery (WSES)
made an additional contribution to the debate regarding
proper antimicrobial drug methodology [11]. The WSES
guidelines outline the proper antimicrobial strategies to
address biliary, extrabiliary, community-acquired, and
hospital-acquired intra-abdominal infections. The au-
thors maintain that arbitrarily determined “default” anti-
biotic regimens that do not take into account the
circumstances of individual cases result in poorer patient
outcomes than do scrupulously customized regimens.
The aim of this study is to compare the efficacy and
safety of a three-day treatment regimen of Ampicillin-
Sulbactam to that of a three-day regimen of Ertapenem
in patients with localized peritonitis ranging from mild
to moderate severity. The authors define localized peri-
tonitis as an infectious process that extends beyond a
singularly affected viscus into the peritoneal space with-
out involving the entire peritoneal cavity. As in many
other studies, most patients presented with acute
appendicitis.
Morover patients with localized perforated diverticu-
litis without fluid collection were submitted to surgery
and primary anastomosis. We know that it is not the
Table 3 Pathogens recovered and their susceptibilities to Ertapenem group and Ampicillin- Sulbactam group
Ertapenem group Ampicillin Sulbactam group
appendicitis non appendicitis appendicitis non appendicitis
Pathogen S R S R S R S R
Aerobes Gram-positive
Staphylococcus coagulase-negative 1
Staphylococcus haemolyticus 1 2 2 4
Other staphylococci 2 1 3 2
Streptococci 6 2
Enterococcus faecium 3
Enterococcus faecalis 1
Other enterococci 2 2
Aerobes Gram-negative
Escherichia coli 36 9 21 3 23
Enterobacter cloacae 1
Enterobacter faecalis 2
Pseudomonas 2 1
Klebsiella 3
Other Enterobacter spp 2 2
Proteus 2
Serratia 2
Citrobacter
Acinetobacter baumanii 1
Anaerobes
Bacteroides fragilis 5 4 3 4
Clostridium spp 2
Fusobacterium frigens 2
Peptostreptococcus 1
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litis and most of the patients should have been treated
with antibiotics. We performed this laparoscopic ap-
proach also with diagnostic value and with the intention
of a one stage emergency treatment. As underlied in lit-
erature, the heterogeneity of patients with colonic diver-
ticular disease means that treatment should be tailored
on an individual basis [12].
Ertapenem is a long-term acting parenteral Group I
carbapenem, which acts in vitro against most aerobic
and anaerobic bacteria associated with community-
acquired infections. Ampicillin-Sulbactam is a widely
used antibiotic in the treatment of intra-abdominal
infections.
This study demonstrates that a 3-day regimen of
Ertapenem has the same clinical effectiveness as a 3-day
regimen of Ampicillin-Sulbactam in treating patients
with localized intra-abdominal infections. Clinical reso-
lution was achieved in 97% of patients in the Ertapenem
group compared to just 86% of cases in the Ampicillin-Sulbactam group, which represents a statistically signifi-
cant difference (p = 0.03).
Regarding the proper duration of antibiotic therapy,
the authors determined that a 3-day Ertapenem or
Ampicillin-Sulbactam regimen is typically sufficient to
safely and efficiently achieve clinical resolution of infec-
tion. Many clinical parameters and resolution metrics
such as body temperature, white blood cell count, and
normalization of gastrointestinal function are important
factors that must be taken into account when assessing
possible discontinuation of antibiotic treatment. From
this study’s data one can infer that the risk of treatment
failure following suspension of antibiotic treatment is
minimal in patients with no clinical evidence of persist-
ent infection.
The study reported 2 cases of death out of 142
enrolled patients (1.4%), equally distributed between the
two treatment groups. Morbidity cases involved wound
infection (10 patients, 7%) and intra-abdominal infection
(2 patients, 1.4%).
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was evaluated according to APACHE II and MPI scores.
Only 15 patients (10.5%) exhibited an APACHE II score
greater than 10. The results of this study can only be
applied to those patients with localized, community-
acquired intra-abdominal infections who demonstrate
clinical improvement after three days of antibiotic ther-
apy. The results of this study should not be extrapolated
to patients outside of this categorical group. Additional
prospective studies investigating the duration of anti-
biotic regimens should be conducted to confirm these
results.
Conclusion
Reducing the superfluous consumption of antibiotics
reduces the prevalence of bacterial drug resistance and
lessens healthcare costs. Discontinuing antibiotic therapy
after three days of treatment saves valuable hospital
resources by conserving antibiotic medications and
limiting unnecessary nursing care. Ultimately, a 3-day
antibiotic regimen reduces the overall duration of
hospitalization. Based on these preliminary results, the
authors conclude that a 3-day Ertapenem regimen is the
optimum treatment for patients with localized intra-
abdominal infections ranging from mild to moderate
severity.
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